Market Movers (8-K)
See all →NASDAQ
SNPS
Synopsys INCSynopsys, Inc. has amended its previous Form 8-K filing to update estimates for its restructuring plan, now projecting pre-tax charges between $425 million and $500 million.
Worse than expected
NASDAQ
SNPS
Synopsys INCSynopsys reported strong third quarter fiscal year 2026 results, with revenue and non-GAAP EPS exceeding expectations, leading to an increased full-year financial outlook.
Better than expected
NASDAQ
SNPS
Synopsys INCSynopsys, Inc. has reported a change in its executive leadership, with Janet Lee stepping down as General Counsel and Corporate Secretary.
NASDAQ
SNPS
Synopsys INCSynopsys, Inc. has appointed Jesse Cohn of Elliott Investment Management to its Board of Directors as part of a cooperation agreement, expanding the board to 11 members.
NASDAQ
SNPS
Synopsys INCSynopsys reported strong second quarter fiscal year 2026 financial results, exceeding revenue guidance and raising full-year revenue and EPS targets.
Better than expected
NASDAQ
SNPS
Synopsys INCSynopsys stockholders approved the Amended and Restated Equity Incentive Plan and elected ten directors at the 2026 Annual Meeting.
Quarterly Earnings (10-Q)
See all →NASDAQ
SNPS
Synopsys INCSynopsys announced a 42% year-over-year revenue increase in Q3 2026, largely due to the full integration of Ansys, showcasing broad-based strength across its EDA and Design IP segments.
Better than expected
NASDAQ
SNPS
Synopsys INCSynopsys reported a significant 42% revenue increase in its second fiscal quarter of 2026, driven by the integration of Ansys and strong performance in its Design Automation segment, despite a dip in Design IP.
Capital raise
Worse than expected
NASDAQ
SNPS
Synopsys INCSynopsys reports a 66% surge in Q1 fiscal 2026 revenue, largely driven by the Ansys acquisition, while net income and EPS declined due to integration costs and increased interest expense.
Capital raise
NASDAQ
SNPS
Synopsys INCSynopsys reports a significant drop in Q3 net income and EPS due to substantial Ansys acquisition-related costs and increased interest expense, despite overall revenue growth.
Delay expected
Worse than expected
Capital raise
NASDAQ
SNPS
Synopsys INCSynopsys, Inc. reported a 10% increase in Q2 2025 revenue and a 13% rise in operating income, while navigating significant financing activities for its pending $35 billion acquisition of ANSYS, Inc., which led to a substantial increase in long-term debt and a decline in six-month profitability.
Worse than expected
Capital raise
Delay expected
NASDAQ
SNPS
Synopsys INCSynopsys' Q1 2025 revenue decreased by 4% year-over-year, primarily due to the impact of an extra week in the previous year and shifts in customer spending, while the company progresses with its pending acquisition of Ansys.
Worse than expected
Capital raise
Annual Reports (10-K)
NASDAQ
SNPS
Synopsys INCSynopsys achieved 15% revenue growth in fiscal 2025, driven by the Ansys acquisition and Design Automation strength, despite Design IP weakness and increased debt.
Capital raise
Worse than expected
NASDAQ
SNPS
Synopsys INCSynopsys' fiscal 2024 annual report highlights a 15% revenue increase, driven by growth across all product lines and geographies, alongside strategic moves including the pending acquisition of Ansys.
Capital raise
Insider Trading (Form 4)
See all →NASDAQ
SNPS
Synopsys INCForm 4: Synopsys CEO Sells Shares
Sassine Ghazi, PRESIDENT AND CEO and a Director of Synopsys Inc, sold 14,604 shares of common stock on September 15, 2026 for $374.88 per share.
NASDAQ
SNPS
Synopsys INCJanet Lee, GC & Corporate Secretary of Synopsys Inc, reported multiple transactions in common stock on September 1, 2026.
NASDAQ
SNPS
Synopsys INCSassine Ghazi, PRESIDENT AND CEO and a Director of Synopsys Inc, reported a transaction in 27 shares of common stock on August 31, 2026.
NASDAQ
SNPS
Synopsys INCSudhindra Kankanwadi, Deputy CFO & CAO of Synopsys Inc, reported a transaction in 27 shares of common stock on August 31, 2026.
NASDAQ
SNPS
Synopsys INCMichael Ellow, Chief Revenue Officer of Synopsys Inc, reported a transaction in 27 shares of common stock on August 31, 2026.
NASDAQ
SNPS
Synopsys INCForm 4: Synopsys Executive Sells Shares
Geus Aart De, EXECUTIVE CHAIR and a Director of Synopsys Inc, sold 49,641 shares of common stock on August 31, 2026.
Proxy Statements (Def-14A)
NASDAQ
SNPS
Synopsys INCSynopsys reports record fiscal 2025 revenue of $7.054 billion, driven by the strategic acquisition of Ansys, positioning the company as a leader in engineering solutions from silicon to systems.
NASDAQ
SNPS
Synopsys INCSynopsys, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) regarding its upcoming shareholder meeting.
NASDAQ
SNPS
Synopsys INCDEF 14A: Synopsys Seeks Stockholder Approval for Equity Incentive and Stock Purchase Plan Amendments
Synopsys is asking stockholders to approve amendments to its 2006 Employee Equity Incentive Plan and Employee Stock Purchase Plan to increase share reserves and update plan provisions.
Better than expected
NASDAQ
SNPS
Synopsys INCSynopsys amended its bylaws and corporate governance guidelines to strengthen the role of the Lead Independent Director, providing greater oversight of management and enhancing communication with stockholders.
Schedule 13G - Passive Investments
NASDAQ
SNPS
Synopsys INCSCHEDULE: Vanguard Reports 7.48% Stake in Synopsys
Vanguard Capital Management disclosed a beneficial ownership of 7.48% in Synopsys Inc. common stock as of March 31, 2026.
NASDAQ
SNPS
Synopsys INCThe Vanguard Group has filed an amended Schedule 13G for Synopsys Inc., reporting 0% beneficial ownership following an internal corporate realignment.
NASDAQ
SNPS
Synopsys INCCapital World Investors has reported a 4.2% beneficial ownership stake in Synopsys, Inc. common stock.
NASDAQ
SNPS
Synopsys INCCapital World Investors has reported a beneficial ownership of 5.1% in Synopsys, Inc., holding 7,934,173 shares of common stock as of March 31, 2025.